Showing results (101-110 of 279) with videos related to

Sort By:
Pageof 28
Archives of Pathology & Laboratory Medicine|June 7, 2022
Four-Year Laboratory Performance of the First College of American Pathologists In Silico Next-Generation Sequencing Bioinformatics Proficiency Testing SurveysLarissa V Furtado, Rhona J Souers, Patricia Vasalos, et al.
American Journal of Clinical Pathology|March 18, 2015
Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometryKaren M Chisholm, Jason D Merker, Jason R Gotlib, et al.
Cell Reports. Medicine|November 10, 2021
Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasmsZhu Shen, Wenfei Du, Cecelia Perkins, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2015
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-IRuben A Mesa, Srdan Verstovsek, Vikas Gupta, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimensSumanth Mosale Seetharam, Yi Liu, Jason Wu, et al.
Blood Advances|June 14, 2023
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimensSumanth Mosale Seetharam, Yi Liu, Jason Wu, et al.
Leukemia & Lymphoma|December 27, 2019
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019Michel Arock, Karl Sotlar, Jason Gotlib, et al.
British Journal of Haematology|April 5, 2016
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myelomaTamara J Dunn, Shira Dinner, Elizabeth Price, et al.
British Journal of Haematology|February 22, 2017
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosisSrdan Verstovsek, Michael R Savona, Ruben A Mesa, et al.
International Journal of Hematology|May 27, 2018
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myelomaShira Dinner, Tamara J Dunn, Elizabeth Price, et al.
Pageof 28